EUVIMEDEUVIMED entdecken
Crossref

Evaluation of cross‐neutralizing immunity following COVID‐19 primary series vaccination during the Omicron surge in Tanzania

Lilian Nkinda iD, Godfrey Barabona, Isaac Ngare, Emmanuel Nkuwi, Doreen Kamori, Frank Msafiri, Ponsian P Kunambi, Elisha Osati, Benson R Kidenya, Harrison Chuwa, Glory Kinasa, Frank E Hassan und 8 weitere

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Lilian Nkinda und 19 weiteren Autor:innen. Beteiligte Einrichtung: Campus College of Medicine, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: European and Development Clinical Trial Partnership, Amne Salim COVID 19 fund, JSPS KAKENHI Grant-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID‐19 vaccine became available in Tanzania during the first wave of the Omicron variant. During that time community seroprevalence of SARS‐CoV‐2 was already at 50%–80%. To date, it remains largely unknown whether ongoing vaccination with the primary series vaccines has any meaningful immune‐boosting effects against newer Omicron subvariants. Therefore, we tested cross‐neutralizing capacity of antibodies elicited by infection, vaccination, or both against SARS‐CoV‐2 Omicron subvariants BA.1, and the newer subvariants BQ.1.1 and XBB.1.5 . that were unexperienced by this population. Participants who were either SARS‐CoV‐2 infected‐only ( n = 28), infected vaccinated ( n = 22), or vaccinated‐only ( n = 73) were recruited from Dar‐es‐Salaam, Tanzania, between April and December 2022. Plasma 50% neutralization titers (NT 50 ) against SARS‐CoV‐2 wild‐type strain and Omicron subvariants were quantified by a lentiviral‐based pseudo‐virus assay. Percentage of participants with neutralizing activity against WT and BA.1 was high (>85%) but was reduced against BQ.1.1 (64%–77%) and XBB.1.5 (35%–68%) subvariants. The low median cross‐neutralization titer was slightly higher in the infected vaccinated group compared to vaccine‐only group against BQ.1.1 (NT 50 148 vs. 85, p = 0.032) and XBB.1.5 (NT 50 85 vs. 37 p = 0.022) subvariants. In contrast, vaccine‐boost among the infected vaccinated did not result to increased cross‐neutralization compared to infected‐only participants (BQ.1.1 [NT 50 of 148 vs. 100, p = 0.501] and XBB.1.5 [NT 50 86 vs. 45, p = 0.474]). We report severely attenuated neutralization titers against BQ.1.1 and XBB.1.5 subvariants among vaccinated participants, which marginally improved in the infected vaccinated participants. Our findings call for further studies to evaluate effectiveness of the primary series vaccines in preventing severe infection and mortality against the newer variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSARS-CoV-2VaccinationHumansTanzaniaMaleFemaleAdultMiddle AgedYoung AdultNeutralization TestsAdolescent

Stichwörter der Autor:innen

AfricaBQ.1.1SARS‐CoV‐2TanzaniaXBB.1.5neutralizing antibodies

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Campus College of Medicine, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
  • Joint Research Centre for Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Department of Microbiology and Parasitology, University of Dodoma, Dodoma, Tanzania.
  • Muhimbili National Hospital, Dar-es-Salaam, Tanzania.
  • Department of Biochemistry and Molecular Biology, Catholic University of Health and Allied Sciences- Bugando, Mwanza, Tanzania.
  • Aga Khan Hospital, Dar-es-Salaam, Tanzania.

ORCID-Profile: Lilian Nkinda, Takamasa Ueno

Förderung

  • European and Development Clinical Trial Partnership
  • Amne Salim COVID 19 fund
  • JSPS KAKENHI Grant-in-Aid for Scientific Research
  • JSPS Bilateral Open Partnership Joint Research Project
  • JSPS Core-to-Core Program

Zitieren

APA

Nkinda, L., Barabona, G., Ngare, I., Nkuwi, E., Kamori, D., Msafiri, F., Kunambi, P. P., Osati, E., Kidenya, B. R., Chuwa, H., Kinasa, G., Hassan, F. E., Judicate, G. P., Gasper, J., Kisuse, J., Mfinanga, S., Senkoro, M., Ueno, T., Lyamuya, E., & Balandya, E. (2024). Evaluation of cross‐neutralizing immunity following COVID‐19 primary series vaccination during the Omicron surge in Tanzania. Journal of Medical Virology. https://doi.org/10.1002/jmv.29822

Vancouver

Nkinda L, Barabona G, Ngare I, Nkuwi E, Kamori D, Msafiri F, et al. Evaluation of cross‐neutralizing immunity following COVID‐19 primary series vaccination during the Omicron surge in Tanzania. Journal of Medical Virology. 2024. doi:10.1002/jmv.29822

BibTeX
@article{Nkinda2024,
  author = {Nkinda, Lilian and Barabona, Godfrey and Ngare, Isaac and Nkuwi, Emmanuel and Kamori, Doreen and Msafiri, Frank and Kunambi, Ponsian P and Osati, Elisha and Kidenya, Benson R and Chuwa, Harrison and Kinasa, Glory and Hassan, Frank E and Judicate, George P and Gasper, Joseph and Kisuse, Juma and Mfinanga, Sayoki and Senkoro, Mbazi and Ueno, Takamasa and Lyamuya, Eligius and Balandya, Emmanuel},
  title = {Evaluation of cross‐neutralizing immunity following COVID‐19 primary series vaccination during the Omicron surge in Tanzania},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29822}
}
Kostenlos starten →